Physician profile
Amy M Bennett
NPI 1467758904
$2,934.76
in general payments reported to CMS, 2019-2025
31 companies · $997 in 2025
The $997 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $667 · 2022: $816 · 2023: $136 · 2024: $319 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $341.59 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $221.20 | 2021-2025 | |
| Dexcom, INC. | $213.01 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $204.18 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $173.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.55 | 2021-2025 | Xifaxan |
| Corium, LLC | $128.88 | 2022 | |
| Astellas Pharma US INC | $103.20 | 2021-2025 | Veozah |
| Amgen INC. | $87.02 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $86.55 | 2022-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.07 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $80.17 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $75.91 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.49 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $60.38 | 2021-2023 | Watchman |
| Horizon Therapeutics Plc | $59.29 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $50.26 | 2022-2023 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $45.51 | 2024-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $44.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.17 | 2021 | |
| Exact Sciences Corporation | $32.01 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $26.29 | 2021-2022 | |
| Bausch Health US, LLC | $19.67 | 2022 | |
| Esperion Therapeutics, INC. | $16.98 | 2023 | Nexletol |
| Collegium Pharmaceutical, INC. | $16.53 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $15.65 | 2025 | Qelbree |
| Sumitomo Pharma America, INC. | $15.52 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $13.84 | 2025 | Quviviq |
| Medtronic, INC. | $11.91 | 2021 | |
| Scynexis, INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.